Product Development Pipeline

The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day (see Product Showcase). There are over a thousand inventions from the Intramural Programs that are currently available for licensing to companies for commercial development (see Licensing Opportunities). Many inventions, however, have been licensed and are now in clinical development with the hope of eventually reaching the market. These are displayed in the Product Development Pipeline.

Phase II
Product Pipeline Licensee Category Pipeline Application Indication IC Pipeline Application
Amatuximab (MORab-009) Morphotek Cancer Therapeutic Mesothelin-expressing cancer NCI Therapeutic
BIO 300 Henry Jackson Foundation/Humanetics Cancer Therapeutic Acute radiation syndrome NCI Therapeutic
DENVax Takeda Vaccines (Montana) Inc. Infectious Disease Vaccine Dengue haemorrhagic fever Vaccine
Oncoprex® Genprex Cancer Therapeutic Lung cancer NCI Therapeutic
Patritumab (U3-1287) U3 Pharma/Daiichi Sankyo Cancer Therapeutic Solid tumors NCI Therapeutic
Proellex® Repros Therapeutics Cardiovascular Therapeutic Anemia associated with uterine fibroids NICHD Therapeutic
Resimmune™ Angimmune Cancer Therapeutic T cell lymphoma NIMH Therapeutic
RGN-137 RegeneRX Biopharmaceuticals Inflammatory Disease Therapeutic Wound healing (Epidermolysis bullosa, Pressure ulcers, Venous stasis ulcers) NIDCR Therapeutic
RotaShield® International Medica Foundation Infectious Disease Vaccine Rotavirus NIAID Vaccine
Sodium nitrite injection Hope Pharmaceuticals Cardiovascular Therapeutic Cerebral vasospasm, Ischemia-reperfusion injury NHLBI Therapeutic
SQ109 Sequella Infectious Disease Therapeutic Tuberculosis NIAID Therapeutic
TG-4010 Transgene Cancer Therapeutic Lung cancer NIAID Therapeutic
Phase III
Product Pipeline Licensee Category Pipeline Application Indication IC Pipeline Application
Dengue fever vaccine Fundação Butantan Infectious Disease Vaccine Dengue haemorrhagic fever NIAID Vaccine
PROSTVAC® BN Immunotherapeutics Cancer Vaccine Prostate cancer NCI Vaccine
RGN-259 RegeneRX Biopharmaceuticals Ophthalmological Therapeutic Dry eye, Neurotropic keratitis NIDCR Therapeutic
Phase I
Product Pipeline Licensee Category Pipeline Application Indication IC Pipeline Application
IV Fenretinide (4-HRP) CerRx Cancer Therapeutic Solid tumors and lymphoma NCI Therapeutic
JX-929 Jennerex Cancer Therapeutic Various cancers NCI Therapeutic
Posiphen® and BNC QR Pharma/Raptor Pharmaceuticals Neurological Therapeutic Parkinson's and Alzheimer's diseases NIA Therapeutic
RGN-352 injectable RegeneRX Biopharmaceuticals Cardiovascular Therapeutic Acute myocardial infarction, Peripheral neuropathy, Stroke NIDCR Therapeutic
SQ109 Sequella Infectious Disease Therapeutic H. pylori infections (gastritis, ulcers, carcinomas) NIAID Therapeutic
StarGen™ Oxford Biomedica Ophthalmological Therapeutic Stargardt disease (juvenile macular degeneration) NCI Therapeutic

This information is updated periodically from information found at ClinicalTrials.gov, company websites, and other publicly-available resources.

Updated: November 2016